Your browser doesn't support javascript.
loading
Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary.
Sanders-Beer, Brigitte E; Archin, Nancie M; Brumme, Zabrina L; Busch, Michael P; Deleage, Claire; O'Doherty, Una; Hughes, Stephen H; Jerome, Keith R; Jones, R Brad; Karn, Jonathan; Kearney, Mary F; Keele, Brandon F; Kulpa, Deanna A; Laird, Gregory M; Li, Jonathan Z; Lichterfeld, Mathias D; Nussenzweig, Michel C; Persaud, Deborah; Yukl, Steven A; Siliciano, Robert F; Mellors, John W.
Afiliación
  • Sanders-Beer BE; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Archin NM; Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Brumme ZL; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Busch MP; Vitalant Research Institute, University of California, San Francisco, California, USA.
  • Deleage C; AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research (FNLCR), Frederick, Maryland, USA.
  • O'Doherty U; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Hughes SH; HIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, Maryland, USA.
  • Jerome KR; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Jones RB; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Karn J; Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA.
  • Kearney MF; HIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, Maryland, USA.
  • Keele BF; AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research (FNLCR), Frederick, Maryland, USA.
  • Kulpa DA; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Laird GM; Accelevir Diagnostics, Baltimore, Maryland, USA.
  • Li JZ; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Lichterfeld MD; Brigham and Women's Hospital and Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
  • Nussenzweig MC; Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
  • Persaud D; Department of Pediatric Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Yukl SA; Department of Medicine, University of California San Francisco (UCSF) and San Francisco VA Medical Center, San Francisco, California, USA.
  • Siliciano RF; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Mellors JW; Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
AIDS Res Hum Retroviruses ; 2023 Jun 19.
Article en En | MEDLINE | ID: mdl-37126090
Since the first HIV-cured person was reported in 2009, a strong interest in developing highly sensitive HIV and SIV reservoir assays has emerged. In particular, the question arose about the comparative value of state-of-the-art assays to measure and characterize the HIV reservoir, and how these assays can be applied to accurately detect changes in the reservoir during efforts to develop a cure for HIV infection. Second, it is important to consider the impact on the outcome of clinical trials if these relatively new HIV reservoir assays are incorporated into clinical trial endpoints and/or used for clinical decision-making. To understand the advantages and limitations and the regulatory implications of HIV reservoir assays, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored and convened a meeting on September 16, 2022, to discuss the state of knowledge concerning these questions and best practices for selecting HIV reservoir assays for a particular research question or clinical trial protocol.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: AIDS Res Hum Retroviruses Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: AIDS Res Hum Retroviruses Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos